A new long-term US study has raised an uncomfortable question for global healthcare systems and the pharmaceutical industry: why is chronic obstructive pulmonary disease (COPD) still largely treated as a condition for “breathing better” when it appears to shorten life almost as aggressively as diabetes and hypertension, conditions that already have massive drug pipelines focused on extending survival?

The findings, published from the National Heart, Lung, and Blood Institute (NHLBI) Pooled Cohorts Study, suggest that COPD may be one of the most underestimated life-threatening diseases in modern medicine. Researchers analysing data from more than 45,000 adults across eight US population-based cohorts found that moderate-to-severe COPD was linked to years of life lost comparable to—and in some cases worse than—diabetes, hypertension, obesity, and even smoking itself.

For millions of patients, the numbers are startling.

The study found that a 65-year-old person without COPD could expect to live another 21.5 years on average. But life expectancy dropped steadily with disease severity. Patients with GOLD Stage 2 COPD lost nearly 2.6 years of life; Stage 3 lost more than 5 years, while Stage 4 COPD reduced life expectancy by more than 7 years.

Researchers noted that the mortality burden of COPD stages 2 to 4 was “similar or greater” than hypertension and diabetes.

That comparison may prove explosive for the pharmaceutical sector.

For decades, diabetes and heart disease have attracted enormous investment into drugs designed not only to control symptoms but also to help patients live longer. Entire therapeutic empires have emerged around statins, ACE inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors. COPD, by contrast, still relies heavily on inhalers that mainly ease symptoms or reduce flare-ups.

The result, respiratory experts argue, is a dangerous therapeutic vacuum.

“This study forces a rethinking of COPD as merely a smoker’s disease or a late-stage breathing disorder,” the researchers observed, adding that COPD was associated with lower life expectancy, "including in adults who never smoked."

That finding may be the study’s most socially disruptive conclusion.

Around 24% of adults with COPD in the United States are lifelong non-smokers. Yet the study found that non-smokers with COPD lost almost the same number of years of life as smokers with the disease. That weakens a long-standing assumption that COPD is mainly a self-inflicted condition caused by tobacco use.

Instead, scientists increasingly point toward air pollution, occupational dust exposure, biomass fuel smoke, poor childhood lung development, repeated infections, and accelerated biological ageing as possible contributors.

Experts say that many patients receive their diagnoses too late.

Stage 2 COPD—often dismissed as a "mild" disease—already carries a years-of-life-lost burden comparable to hypertension. Yet many patients at this stage continue with persistent coughs, fatigue, or breathlessness for years before undergoing spirometry, the lung function test used to diagnose COPD.

Inside pulmonary research laboratories, the challenge is becoming more urgent. Unlike diabetes or cardiovascular medicine, respiratory science still lacks a widely accepted drug capable of directly slowing lung ageing or restoring damaged air sacs. In various lung research labs in Boston and California, scientists are currently exploring ways to reduce inflammation, use stem cells for healing, and develop treatments to protect lung tissue before it gets permanently damaged.

The study also highlighted how COPD silently fuels other deadly diseases. Researchers noted that COPD patients face a two- to five-fold higher risk of heart disease and a two- to four-fold higher risk of lung cancer, even in milder stages.

For public health experts, the implications extend beyond hospitals.

If insurers and governments are willing to fund expensive diabetes medicines because they save years of life, respiratory specialists argue that similar value-based investment models may now be justified for advanced COPD therapies and earlier intervention programs.

The researchers concluded that “more research and public health initiatives are needed to improve survival".

That sentence sounds restrained. But behind it lies a growing global concern: millions of people may already be losing years of life from a disease still too often treated as little more than chronic breathlessness.